Arch Therapeutics Co-Founder Rutledge Ellis-Behnke, PhD Presents at Two Scientific Meetings in March

Arch Therapeutics Co-Founder Rutledge Ellis-Behnke, PhD Presents at Two
Scientific Meetings in March
Discusses AC5(TM) at the Brainstorming Neuromodulation Workshop and
4th Annual Meeting of American Society of Nanomedicine
WELLESLEY, MA -- (Marketwired) -- 03/26/14 -- Rutledge
Ellis-Behnke, PhD, co-founder and inventing scientist at Arch
Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or "the Company"), a life
sciences company and developer of the AC5 Surgical Hemostatic
Device(TM), a novel product aimed at controlling bleeding and fluid
loss in order to provide faster and safer surgical and interventional
care, presents his work using AC5(TM) at two scientific meetings.
At the upcoming 4th Annual Meeting of the American Society for
Nanomedicine in Rockville, Maryland on March 28-30, Dr. Ellis-Behnke
will present his hemostasis and tissue stabilization work using
self-assembling compositions, including AC5 and other compositions
that have been licensed to Arch. Dr. Ellis-Behnke will present on
Saturday, March 30 at 9:25 AM EST in a talk titled "New Molecular
Medical Devices: A Framework, Objective Measures and Treatments That
Can Help Restore the Body to a Pre-injury State."
Information about the American Society for Nanomedicine may be found
on their website at the following link http://amsocnanomed.org.
Dr. Ellis-Behnke noted, "The use of AC5 to control bleeding during
surgery also stabilizes the tissue, which increases the stability of
any implantable device. By quickly stopping bleeding, there is little
or no edema and the leads will stay where they are placed. Revisions
can be greatly reduced. Additionally, through the stabilization of
tissue and hemostatic activity, the severity of the damage from
trauma and disease can be significantly mitigated, thus reducing
recovery time and the risk of developing secondary damage or
infection."
He continued, "Arch Therapeutics' work is of vital importance in this
field as it is instrumental in understanding how to translate these
discoveries into commercially viable processes and products designed
to fulfill areas of extraordinary medical need."
Also, at the recent "Brainstorming Neuromodulation" workshop in
Carmel, California held on March 14-16, Dr. Ellis-Behnke showed how
AC5 stops bleeding during brain surgery. This biannual,
invitation-only workshop was organized by Bay Area neurologist
Russell Andrews, MD, Medical Advisor for Neurosurgery at NASA Ames
Research Center and President of the International Conference on
Neuroprotective Agents.
Terrence W. Norchi, M.D., Chief Executive Officer of Arch
Therapeutics, said, "We continue to be grateful to Dr. Ellis-Behnke
for his work on behalf of the Company, both in terms of his
scientific contributions to the development of AC5 and his ongoing
outreach to the scientific community to convey AC5's unique
benefits."
About Arch Therapeutics, Inc.
Arch Therapeutics, Inc. is a medical
device company developing a novel approach to stop bleeding
(hemostasis) and control leaking (sealant) during surgery and trauma
care. Arch is developing products based on an innovative
self-assembling peptide technology platform to make surgery and
interventional care faster and safer for patients. Arch's flagship
development stage product candidate, known as AC5(TM), is being
designed to achieve hemostasis in minimally invasive and open
surgical procedures.
Find out more at www.archtherapeutics.com.
Notice Regarding Forward-Looking Statements
This news release
contains "forward-looking statements" as that term is defined in
Section 27(a) of the Securities Act of 1933, as amended, and Section
21(e) of the Securities Exchange Act of 1934, as amended. Statements
in this press release that are not purely historical are
forward-looking statements and include any statements regarding
beliefs, plans, expectations or intentions regarding the future. Such
forward-looking statements include, among other things, references to
novel technologies and methods, our business and product development
plans and projections, or market information. Actual results could
differ from those projected in any forward-looking statements due to
numerous factors. Such factors include, among others, the inherent
uncertainties associated with developing new products or technologies
and operating as a development stage company, our ability to retain
important members of our management team and attract other qualified
personnel, our ability to raise the additional funding we will need
to continue to pursue our business and product development plans, our
ability to develop and commercialize products based on our technology
platform, and market conditions. These forward-looking statements are
made as of the date of this news release, and we assume no obligation
to update the forward-looking statements, or to update the reasons
why actual results could differ from those projected in the
forward-looking statements. Although we believe that any beliefs,
plans, expectations and intentions contained in this press release
are reasonable, there can be no assurance that any such beliefs,
plans, expectations or intentions will prove to be accurate.
Investors should consult all of the information set forth herein and
should also refer to the risk factors disclosure outlined in the
reports and other documents we file with the SEC, available at
www.sec.gov.
On Behalf of the Board,
Terrence W. Norchi, MD
Arch Therapeutics,
Inc.
Contact:
ARTH Investor Relations
Toll Free: +1-855-340-ARTH (2784) (US and Canada)
Email: investors@archtherapeutics.com
Website: www.archtherapeutics.com